Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 0.1 mg injection once weekly
DULA_SC_0p1MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.60 (0.01 to 48.35) | 0.44 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.16 (0.00 to 2.70) | 0.82 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.60 (0.90 to 12.05) | 0.39 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.00 (0.07 to 7.08) | 0.71 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.08 (0.16 to 4.87) | 0.63 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.68 (0.06 to 4.22) | 0.71 |